Literature DB >> 18718658

Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes.

Chikako Satoh1, Hideto Tamura, Taishi Yamashita, Takashi Tsuji, Kazuo Dan, Kiyoyuki Ogata.   

Abstract

Clinical data suggest that CD7+ myeloblasts are linked with poor prognosis in myeloid malignancies including myelodysplastic syndromes (MDS). To explore the biology behind this, we compared cell characteristics between CD34+CD7+ and CD34+CD7- myeloblasts from an MDS cell line and fresh samples from MDS patients. Compared with CD34+CD7- myeloblasts, CD34+CD7+ myeloblasts showed greater proliferative capacity, more active cell cycling, and less apoptosis. In analyses of a cell line, CD34+CD7+ myeloblasts produced CD34+CD7- myeloblasts and showed lower expressions of interleukin-8 and chemokine (C-C motif) ligand 2 genes, suggesting immaturity of these cells. These findings might underlie the clinical aggressiveness in CD7+ MDS.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18718658     DOI： 10.1016/j.leukres.2008.07.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

1.  CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.

Authors:  Diogo Gomes-Silva; Erden Atilla; Pinar Ataca Atilla; Feiyan Mo; Haruko Tashiro; Madhuwanti Srinivasan; Premal Lulla; Rayne H Rouce; Joaquim M S Cabral; Carlos A Ramos; Malcolm K Brenner; Maksim Mamonkin
Journal:  Mol Ther       Date:  2018-10-04       Impact factor: 11.454

2.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 3.  5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).

Authors:  Hiroshi Ureshino; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Atsujiro Nishioka; Takero Shindo; Yasushi Kubota; Toshihiko Ando; Kensuke Kojima; Shinya Kimura
Journal:  Int J Hematol       Date:  2016-12-02       Impact factor: 2.490

4.  CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation.

Authors:  Sonja Röhrs; Michaela Scherr; Julia Romani; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  J Hematol Oncol       Date:  2010-04-14       Impact factor: 17.388

5.  Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

Authors:  U Oelschlaegel; M Alexander Röhnert; B Mohr; K Sockel; S Herold; G Ehninger; M Bornhäuser; C Thiede; U Platzbecker
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

6.  Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes.

Authors:  Bettina Kárai; Eszter Szánthó; János Kappelmayer; Zsuzsa Hevessy
Journal:  EJIFCC       Date:  2013-01-16

Review 7.  Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

Authors:  Mingxue Fan; Minghao Li; Lipeng Gao; Sicong Geng; Jing Wang; Yiting Wang; Zhiqiang Yan; Lei Yu
Journal:  J Hematol Oncol       Date:  2017-08-29       Impact factor: 17.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.